GENE ONLINE|News &
Opinion
Blog

2020-11-26| Asia-PacificCOVID-19

Medigen Signs Agreement with Metronic, Making it the First Taiwan-made Vaccine Deal

by Tyler Chen
Share To

Image courtesy: Medigen Biotechnology Corp.

As Pfizer/BioNtech, AstraZeneca, and Moderna are making progress in clinical trials and signing deals for distributing millions of vaccines, Taiwan has officially entered the fray, making the first agreement of its self-developed COVID-19 vaccines MVC-COV1901 on November 20, bagging up to 150 million dollars.

Medigen Vaccine Biologics (MVC), a pharmaceutical manufacturer in Taiwan, lately signed a Memorandum of Agreement (MOA) with Metronic Medicare Sdn Bhd (MMSB) which acquired the exclusive rights to distribute MVC-COV1901 in Malaysia.

 

MVC-COV1901

MVC-COV1901 consists of a genetically recombinant S-2P spike protein designed by the U.S. National Institutes of Health (NIH) and CpG-1018 adjuvant from a US biopharmaceutical company Dynavax. The vaccine has entered the Phase 1 clinical trial in September 2020 in Taiwan, and it is expected to set foot in a multi-regional Phase 2 trial in December with 3,700 patients.

To accelerate the process, on November 3, the MVC announced the partnership with NIHE, a public institute under the Ministry of Health in Vietnam. MVC-COV1901 will run Phase 2 trials both in Taiwan and Vietnam for acquiring EUA in Taiwan and other areas as soon as possible. This will allow MVC to begin manufacturing of MVC-COV1901 in 2021 for around 10 to 20 million doses.

 

Details of the MOA

According to the MOA, MVC will supply 1 to 3 million doses in the form of pre-filled syringes or multi-dose vials with up to 50 dollars apiece throughout 2021.

It should be noted that the specific price is still under negotiation and that MMSB would have to wait until MVC-COV1901 is granted EUA to receive vaccines in the second half of 2021. Moreover, the exact numbers of vaccines purchased will be settled at the end of 2020, and at least 3 months of lead time will be allowed between the purchase and delivery of the vaccines.

As for the clinical development of MVC-COV1901 in Malaysia, MMSB is responsible for the expense and cost while MVC will supply vaccines at a discounted price for the trials.

By Tyler Chen

Related Article: Taiwanese Government Grants 16 Million to aid Adimmune’s COVID-19 Vaccine Trials

References
  1. https://disclosure.bursamalaysia.com/FileAccess/apbursaweb/download?id=109178&name=EA_GA_ATTACHMENTS

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
R&D
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
Saudi Arabia Reveals Grand Ambition to Become a Global Biotech Powerhouse by 2040
2024-01-26
An Interview with AusBiotech CEO Lorraine Chiroiu, Highlighting Innovations and Growth in the Australian Biotech Sector
2023-12-16
LATEST
Topo-1 and FRα: Key Focus Areas and Major Collaborations in ADC Research – Part I
2024-07-23
Eli Lilly’s Tirzepatide Gets Approval in China for Weight Loss Management
2024-07-22
Roche Reports Positive Clinical Trial Results for Two Diabetes-Related Eye Disease Therapies
2024-07-19
7th Person in History Possibly Cured From HIV After Stem Cell Transplant for Acute Myeloid Leukemia
2024-07-19
Large RCT Finds Time-Lapse Imaging for Embryo Selection in IVF Does Not Improve Live Birth Rates
2024-07-19
Assessment of Supply Chain Risk Key to Improving Medicine Access
2024-07-18
SK Biopharma and Full-Life Sign US$571.5 Million Deal for Innovative Radiopharmaceutical FL-091
2024-07-18
EVENT
Scroll to Top